BIOMARKER FOR ALZHEIMER’S DISEASE
|Posted date||May 7, 2019|
|International application number||2018JP018849|
|International publication number||WO 2018221212|
|Date of international filing||May 16, 2018|
|Date of international publication||Dec 6, 2018|
|Title||BIOMARKER FOR ALZHEIMER’S DISEASE|
|Abstract||The present invention addresses the problem of providing a marker and an application thereof useful for early diagnosis or differentiation of Alzheimer’s disease. Provided is a biomarker for Alzheimer’s disease, comprising a blood-borne flotillin.|
|Outline of related art and contending technology||
Consisting of the senile plaques in the brain to the deposition of amyloid beta protein, Alzheimer's disease (hereinafter, abbreviated as' AD ' may be) of the pathological observations and the most representative, or the deposition of amyloid formation of the polymer to cause the onset of AD are considered. Amyloid beta (A β) metabolism is therefore (production, polymer formation, as well as decomposition, removing) the adjustment of the prevention of a disease, is considered to be the target of treatment, therapeutic drug development has been performed. According to a recent study, 20 years or more before the onset of AD A β aggregates form of senile plaques were deposited at the beginning, at the onset of a brain plaques is already present in a range becomes clear. (Tau) then the tau protein aggregates the neurofibrillary tangles as a main component and will appear, mild cognitive impairment (Mild Cognitive Impairments; MCI) via a developing dementia is considered. Receives such results of studies, the National Institute on Aging (NIA; Alzheimer's disease Society National Institute on Aging) diagnostic criteria and a revised version of the year 2011, or not brain pathology condition change step of the 'before the onset of Alzheimer's disease (Preclinical AD) ' proposed (Non-Patent Document 1) have been invented. In addition, such as amyloid vaccine therapy treatment is the root to the target, after the onset of the effect to be limited to the invention will become apparent, senile plaques is already completed after the onset of amyloid pathology progresses than be treated prior to the onset is considered to be in. Under such a background, using PET image inspection or cerebrospinal fluid such as amyloid imaging method, the AD and mild cognitive impairment (MCI) prior to the onset of treatment and diagnostic stage is attempted and made an attempt, the stage of the possible in the art. However, with invasive examination of the cerebrospinal fluid, generally in the office or hospital is difficult. In addition, the device may be expensive and reagent PET, in addition to the possibility of radiation damage cannot be denied. From such a background, a more simple inexpensive small and minimally invasive diagnostic method has been expected development. On the other hand, other dementia Alzheimer's dementia is, Lewy body dementia, vascular dementia, frontotemporal dementia (FTD) type and the like, suitable for the prevention/treatment is necessary for the differential diagnosis. In fact, such as a depression in the elderly patient, Alzheimer's dementia often requires discrimination of the case.
On the other hand, in the brain that exosomes A β protein to present, to serve to remove the reported findings, in the development of AD role of exosomes is attracting attention. However, for the change in the level of exosomes AD was completely unknown. In this regard, studies of the inventors of the present invention group, in the cells treated with Aβ1-42, the secretion of exosomes reported phenomenon is significantly reduced (non-patent document 2).
|Scope of claims||
(In Japanese)請求の範囲 [請求項1]
|IPC(International Patent Classification)||
Contact Information for " BIOMARKER FOR ALZHEIMER’S DISEASE "
- Nagoya City University Liaison Center
- URL: https://www.nagoya-cu.ac.jp/
- Address: 1, Aza Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya-shi, Aichi, Japan , 467-8601
- Fax: 81-52-841-0261